Amphista Therapeutics Ltd
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.
This is a modular, Phase 1, open-label, multi-centre dose-escalation study investigating AMX-883 in participants with relapsed/refractory AML and high-risk MDS. The study comprises Module 1, which will evaluate AMX-883 as monotherapy and in combination with posaconazole. Module 1 consists of three parts: * Part A consists of the monotherapy dose escalation cohorts and investigation of the food-effect at selected dose(s). * Part B consists of AMX-883 in combination with posaconazole dose escalation cohorts. Other modules may be added by protocol amendment. The study aims to establish optimal…
Inclusion Criteria: * Participants with relapsed or refractory AML who have failed all available standard therapies or relapsed or refractory high-risk MDS with BM blasts 10-19% * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Adequate washout from prior therapies * Adequate kidney and liver function * Female participants of childbearing potential must use highly effective contraception for at least 120 days, or 27 weeks (applicable to the United Kingdom \[UK\] only), after last dose, and male participants must agree to use barrier contraception and avoid sperm donation…
AMX-883 will be administered orally.
Posaconazole tablets will be administered orally.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.